Innoviva

Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GlaxoSmithKline

With the approval for the asthma indication, Glaxo's (GSK) Trelegy becomes the first single inhaler triple therapy approved for the maintenance treatment of both asthma and COPD.

Glaxo/Innoviva's Trelegy Ellipta Gets FDA Nod for Asthma

The U.S. Food and Drug Administration (FDA) has approved Innoviva Inc.’s (NASDAQ: INVA) treatment of asthma and for patients with chronic obstructive pulmonary disease (COPD), the company announced, giving shares a boost early Thursday.

Innoviva Wins Another Key FDA Approval for Asthma

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) announced the US Food and Drug Administration (FDA) has approved a new indication for Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol ‘FF/UMEC/VI’) for the treatment of asthma in patients aged 18 years and older adding to its current license for use in patients with chronic obstructive pulmonary disease (COPD). Trelegy Ellipta is not indicated for relief of acute bronchospasm.

FDA Approves Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Both Asthma and COPD in the US

Innoviva (INVA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Innoviva (INVA) in Focus: Stock Moves 7% Higher

Jazz Pharmaceuticals

Theravance Biopharma

10X Genomics

These shell companies allow the businesses they acquire to go public much more quickly than an IPO would. Is it time to buy in?

Why This Top Venture Capitalist Is Raising Money With a Biotech SPAC

Fortune Brands Home & Security

Labcorp Holdings Inc

Thor Industries

Williams-Sonoma

The Dow was lower this morning, on the day that they make major changes to their constituents after Apple's share split reduced tech influence in the index.

Top Stocks To Buy Today As Investors Rush To Buy Apple After Split

Dominion Energy

P. H. Glatfelter Company

Vulcan Materials

All major indices are in the green as the investors digested the speech by the Federal Reserve, taken as positive for equities. Tech stocks have also been driving the markets higher, propelling indices to all-time highs.

Best Stocks To Buy Today As Fed Speech Drives Markets Higher

Alexion Pharma

These two stocks are probably undervalued, but that won’t last forever.

2 Best Biotech Stocks to Buy in August

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc.

Innoviva Reports Second Quarter 2020 Financial Results

During Innoviva's (INVA) upcoming Q2 earnings call, investor focus will be on the royalties earned that comprise the company's top line.

Innoviva (INVA) to Report Q2 Earnings: What's in the Cards?

Is  (INVA) Outperforming Other Medical Stocks This Year?

Has Innoviva (INVA) Outpaced Other Medical Stocks This Year?

Innoviva (INVA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Innoviva (INVA) Looks Good: Stock Adds 8.9% in Session

Innoviva (INVA) closed at $14.13 in the latest trading session, marking a -0.77% move from the prior day.

Innoviva (INVA) Stock Moves -0.77%: What You Should Know

Genmab - ADR

iShares Nasdaq Biotechnology ETF

Novavax

Trillium Therapeutics

Vanda Pharmaceuticals

Vertex Pharmaceuticals

XBiotech

These are the biotech stocks with the best value, fastest growth, and most momentum for Q3 2020.

Top Biotech Stocks for Q3 2020

Innoviva (INVA) closed the most recent trading day at $13.92, moving +0.43% from the previous trading session.

Innoviva (INVA) Gains But Lags Market: What You Should Know

Innoviva (INVA) closed at $14.36 in the latest trading session, marking a -1.64% move from the prior day.

Innoviva (INVA) Dips More Than Broader Markets: What You Should Know

Is Innoviva (INVA) Stock Outpacing Its Medical Peers This Year?

Moderna

Sanofi

Gilead Sciences

Pfizer

As drug makers race to develop vaccine to fight coronavirus, we shortlist five stocks that are poised to grow on progress in clinical trials.

5 Stocks to Buy as Coronavirus Vaccine in Human Trails Ramp Up

As of late, it has definitely been a great time to be an investor in Innoviva.

Innoviva's Shares March Higher, Can It Continue?

AbbVie

Eli Lilly

Another drug is being tested to kill the virus (if we can figure out administration on humans).

Another Drug to Fight Coronavirus & 3 Picks

Amgen

Biogen

CRISPR Therapeutics

Editas Medicine

Regeneron Pharmaceuticals

Biotech stocks pulled off an impressive rally to finish 2019 strong. These names in the industry are looking to do the same in 2020.

7 Biotech Stocks to Buy and Hold in 2020

Alamos Gold

Equinox Gold Corp

Franco-Nevada C

Kirkland Lake Gold

Gold prices are currently at seven-year highs as investors are flocking to buy gold amid fears of the coronavirus outbreak and economic slowdown.

5 Stocks to Grab as Gold Prices Surge on Coronavirus Fears

Innoviva (INVA) closed at $13.91 in the latest trading session, marking a +0.87% move from the prior day.

Innoviva (INVA) Outpaces Stock Market Gains: What You Should Know

Innoviva (INVA) closed at $14.25 in the latest trading session, marking a -0.84% move from the prior day.

Innoviva (INVA) Stock Moves -0.84%: What You Should Know

Exelixis

These promising stocks have been flying under the radar this year, but they're worth another look.

2 Incredibly Cheap Biotech Stocks

News for Innoviva Stock (INVA)